Eugenia Morelos-Figaredo
Research Subjects
Eugenia Morelos-Figaredo has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Evelyn Ruiz Contreras
Laboratorio de Neurogenomica Cognitiva, Unidad de Psicobiologia y Neurociencias, Facultad de Psicologia, Universidad Nacional Autonoma de Mexico, Av. Universidad 3004, Ciudad de Mexico, 04510, Mexico
2 shared publications - Alejandra Lázaro-Figueroa
Laboratorio de Neurogenómica Cognitiva, Facultad de Psicología, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México
2 shared publications - Alejandra Medina-Rivera
Laboratorio Internacional de Investigacion sobre el Genoma Humano, Universidad Nacional Autonoma de Mexico, Queretaro, Queretaro, Mexico
2 shared publications - Alejandra Zayas-Del Moral
Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca, México
2 shared publications Ana P. Angulo-Arrieta
Hospital Angeles Puebla, Puebla, Mexico
2 shared publicationsAraliz López-Pintor
Hospital Angeles Puebla, Puebla, Mexico
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 38 (1)
Does cognitive performance decline as a function of age at onset in Parkinson’s disease? the role of age at assessment, education, and clinical severity
- 4 August 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 38 (1)
Open AccessDoes cognitive performance decline as a function of age at onset in Parkinson’s disease? the role of age at assessment, education, and clinical severity
- Open Access
Clinical and genetic insights of Parkinson’s Disease in a Mexican cohort: highlighting Latino’s diversity
Objective: This study aims to describe the establishment of the Mexican Parkinson’s Research Network (MEX-PD), a consortium dedicated to investigating the clinical, genetic, environmental, and neurophysiological underpinnings of phenotypic diversity in Mexican Parkinson’s disease (PD) patients and to present preliminary clinical and genetic outcomes. Methods: PD patients and control participants were recruited from medical centers across Mexico. The initial recruitment phase involved comprehensive neurological evaluations, cognitive assessments, and DNA collection. We conducted classical statistical analyses on clinical variables. Secondly, following genotyping with NeuroBooster array, quality control and imputation, preliminary analysis of ancestry composition, allele frequency calculation and association analysis was carried out for 294 samples. Results: The cohort consisted of 530 control participants and 470 PD patients, with a mean age of diagnosis of 59.9 ± 11.52 years. Among the PD patients, 21.2% were identified as having early-onset PD (NOTCH , LRRK2 , MTHFR and KPNA1 emerged as relevant to be prioritized in future studies. Conclusions: The MEX-PD consortium will contribute to the understanding of PD within the Mexican population. The data collected will enable a deeper comprehension of the specific contributions of genetic and environmental factors to these outcomes. Significance: This research advocates for the development of personalized treatments and aims to improve the quality of life for Mexican PD patients.
Open AccessClinical and genetic insights of Parkinson’s Disease in a Mexican cohort: highlighting Latino’s diversity
Objective: This study aims to describe the establishment of the Mexican Parkinson’s Research Network (MEX-PD), a consortium dedicated to investigating the clinical, genetic, environmental, and neurophysiological underpinnings of phenotypic diversity in Mexican Parkinson’s disease (PD) patients and to present preliminary clinical and genetic outcomes. Methods: PD patients and control participants were recruited from medical centers across Mexico. The initial recruitment phase involved comprehensive neurological evaluations, cognitive assessments, and DNA collection. We conducted classical statistical analyses on clinical variables. Secondly, following genotyping with NeuroBooster array, quality control and imputation, preliminary analysis of ancestry composition, allele frequency calculation and association analysis was carried out for 294 samples. Results: The cohort consisted of 530 control participants and 470 PD patients, with a mean age of diagnosis of 59.9 ± 11.52 years. Among the PD patients, 21.2% were identified as having early-onset PD (NOTCH , LRRK2 , MTHFR and KPNA1 emerged as relevant to be prioritized in future studies. Conclusions: The MEX-PD consortium will contribute to the understanding of PD within the Mexican population. The data collected will enable a deeper comprehension of the specific contributions of genetic and environmental factors to these outcomes. Significance: This research advocates for the development of personalized treatments and aims to improve the quality of life for Mexican PD patients.